NASDAQ:GLMD • IL0011313900
Past quarterly earnings results for GALMED PHARMACEUTICALS LTD (GLMD), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | -0.33 | -0.55 | 40.09% | - | - | - | ||
| Q2 2025 | -0.63 | -0.85 | 25.58% | - | - | - | ||
| Q1 2025 | -0.62 | -0.91 | 31.70% | - | - | - | ||
| Q4 2024 | - | - | - | - | ||||
| Q3 2024 | - | - | - | - | ||||
| Q2 2024 | - | - | - | - | ||||
| Q1 2024 | - | - | - | - | ||||
| Q4 2023 | -11.76 | -3.92 | -200.25% | 34.67% | - | - | ||
| Q3 2023 | -2.88 | -3.30 | 12.85% | 92.38% | - | - | ||
| Q2 2023 | -11.40 | -4.16 | -173.93% | 57.78% | - | - | ||
| Q1 2023 | -13.08 | -18.36 | 28.76% | 69.72% | - | - | ||
| Q4 2022 | -18.00 | -25.70 | 29.97% | 66.67% | - | - | ||
| Q3 2022 | -37.80 | -30.29 | -24.78% | 32.26% | - | - | ||
| Q2 2022 | -27.00 | -43.33 | 37.69% | 54.55% | - | - | ||
| Q1 2022 | -43.20 | -58.75 | 26.47% | 36.84% | - | - | ||
| Q4 2021 | -54.00 | -55.54 | 2.77% | 37.50% | - | - | ||
| Q3 2021 | -55.80 | -65.73 | 15.11% | 3.13% | - | - | ||
| Q2 2021 | -59.40 | -70.14 | 15.31% | -26.92% | - | - | ||
| Q1 2021 | -68.40 | -70.69 | 3.23% | -31.03% | - | - | ||
| Q4 2020 | -86.40 | -66.83 | -29.28% | - | - | - | ||
| Q3 2020 | -57.60 | -55.08 | -4.58% | - | - | - | ||
| Q2 2020 | -46.80 | -58.49 | 19.99% | - | - | - | ||
| Q1 2020 | -52.20 | -67.24 | 22.37% | - | - | - |
Notes
GALMED PHARMACEUTICALS LTD (GLMD) last reported earnings on 11/26/2025.
GALMED PHARMACEUTICALS LTD (GLMD) beat EPS estimates and missed revenue estimates in the most recent quarter.